IMP-MEL: A PHASE 1 FIRST-IN-HUMAN DOSE-FINDING STUDY OF A NOVEL INVARIANT NATURAL KILLER T-CELL AGONIST (INKT) IMM60 IN ADVANCED MELANOMA AND NON-SMALL-CELL LUNG CANCER (
JOURNAL FOR IMMUNOTHERAPY OF CANCER（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要